This HTML5 document contains 145 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://dx.doi.org/10.1136/
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q52840577
rdf:type
wikibase:Item
schema:description
teaduslik artikkel artículo científico publicado en 2014 bài báo khoa học مقالة علمية نشرت في 2 يناير 2014 2014年學術文章 2014年の論文 наукова стаття, опублікована в січні 2014 scientific article published on 2 January 2014 2014年學術文章 artigo científico article scientifique article científic article scientific articolo scientifico vědecký článek tieteellinen artikkeli научна статия artikulong pang-agham 2014年学术文章 tudományos cikk מאמר מדעי 2014年学术文章 научни чланак 2014年學術文章 artikel ilmiah บทความทางวิทยาศาสตร์ 2014년 논문 επιστημονικό άρθρο naučni članak scientific article published on 2 January 2014 2014年学术文章 vedecký článok artigo científico scienca artikolo ২ জানুয়ারি ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ სამეცნიერო სტატია научная статья vitskapeleg artikkel wissenschaftlicher Artikel artículu científicu 2014年學術文章 2014年学术文章 2014 nî lūn-bûn videnskabelig artikel 2014年学术文章 2014年學術文章 bilimsel makale scientific article published on 2 January 2014 articol științific научни чланак artigo científico artykuł naukowy мақолаи илмӣ artikull shkencor 2014 թվականի հունվարի 2-ին հրատարակված գիտական հոդված 2014年学术文章 wetenschappelijk artikel vetenskaplig artikel vitenskapelig artikkel
p:P577
wds:Q52840577-6852177B-175C-4588-BAE8-EA269220B29A
wdt:P577
2014-01-02T00:00:00Z
p:P407
wds:Q52840577-614A15F3-7B9E-4002-8B14-B18D54FC42D1
wdt:P407
wd:Q1860
p:P2860
wds:Q52840577-6C161F34-09A6-4D7D-8522-4A6B0F0C6A64 wds:Q52840577-19C309E3-168B-42C7-A2FE-F7BB05CC3200 wds:Q52840577-252E2E89-27B0-4CC8-8E52-EA57637868D9 wds:Q52840577-33C54465-985A-4413-B011-917AB1F7EB07 wds:Q52840577-3F24EAD8-78DF-415E-B82B-DC5FBA383988 wds:Q52840577-4E7A7976-D291-4346-B48F-420443AEC440 wds:Q52840577-ABB77E20-99C9-47A0-BA23-7FA9BED5FF3E wds:Q52840577-C837B999-26D2-4B82-850A-A54E484483BF wds:Q52840577-7C3D4376-BFD6-453D-BBEF-CC38DADA931F wds:Q52840577-9022B568-F818-4CDC-BC04-0B050BC947A7 wds:Q52840577-D33E7E31-2CDE-4DDB-9986-92BF2FA3CB89 wds:Q52840577-55BA5DA1-DC5C-402F-97A4-6348F7D0B5B3
wdt:P2860
wd:Q37210198 wd:Q46161838 wd:Q34508368 wd:Q34110066 wd:Q55049410 wd:Q37298600 wd:Q48029200 wd:Q33899815 wd:Q46848758 wd:Q53239672 wd:Q58327964 wd:Q26828418
p:P2093
wds:Q52840577-B73833DD-7C89-42B7-BC8E-C193C1E0D9BD wds:Q52840577-AD5014CB-1C68-4C2D-A00E-EDE7AA965C8C wds:Q52840577-982267BE-C12C-47C5-B831-9E37BF827411 wds:Q52840577-5F03E607-7187-4F5C-AA39-81875C6B178E wds:Q52840577-E7B43DE9-62FF-4489-AF60-284D592D3937
wdt:P2093
Frederique Ponchel Sarah Horton Edward M Vital Domini Bryer Sudipto Das
rdfs:label
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
skos:prefLabel
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
schema:name
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
p:P50
wds:Q52840577-DBAFE026-37BA-47C0-A8C5-D1D2ECF7317C wds:Q52840577-762F0C82-71B8-48AF-A42D-8D4939BC5559 wds:Q52840577-AF8129CB-B88D-45E2-908C-02E5F17C3FB2 wds:Q52840577-623A879E-0A26-4817-A2E9-E85411D05E14
wdt:P50
wd:Q38544276 wd:Q53476759 wd:Q19859634 wd:Q44940582
p:P1476
wds:Q52840577-9AA9AE80-A422-4CF4-ACED-5E10CAE4435B
wdt:P1476
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
p:P304
wds:Q52840577-93A68EFA-A497-4973-9C6F-B1E1DA32E148
wdt:P304
909-912
p:P31
wds:Q52840577-04B43BF7-13E6-49C0-A19C-A932631DBFB5
wdt:P31
wd:Q13442814
p:P921
wds:Q52840577-1CBAFFBD-2C9A-4332-AAEC-3B763A6E8090 wds:Q52840577-586760C3-99FC-4A27-8AD7-DFB386B0BDD6 wds:Q52840577-CA449362-8AFE-421C-BCAE-292101A933CA
wdt:P921
wd:Q412323 wd:Q187255 wd:Q425154
p:P698
wds:Q52840577-BB70605F-6E4E-4865-B1C2-4746C320C41A
wdtn:P698
n12:24385201
wdt:P698
24385201
p:P5530
wds:Q52840577-DA85DC10-8CAF-46B4-8D5F-2197A4F6322D
wdt:P5530
10.1136/ANNRHEUMDIS-2013-204417
p:P1433
wds:Q52840577-5F183C90-93FD-404D-A433-0226438F2E10
wdt:P1433
wd:Q4767876
p:P433
wds:Q52840577-30F664C8-48F2-46AA-A0AE-AF833BED0903
p:P478
wds:Q52840577-8B9231A6-CCA5-4202-BEF4-2F1AE403D855
wdt:P433
5
wdt:P478
73
p:P356
wds:Q52840577-6E5113E3-E26C-42F9-AEF1-5D21C2A1432E
wdtn:P356
n11:ANNRHEUMDIS-2013-204417
wdt:P356
10.1136/ANNRHEUMDIS-2013-204417
p:P5875
wds:Q52840577-C7662731-71F6-4D4C-A36A-B537388023F6
wdt:P5875
259566826
p:P6179
wds:Q52840577-35214F29-1CD9-4A75-9FE3-2614D9E30EAA
wdt:P6179
1016914467